FMC Corp's stock price surged 5.01% during intraday trading on Monday, following the company's announcement that it is exploring strategic alternatives, including a potential sale.

The agrochemical giant stated that its board has authorized a review of various options to enhance shareholder value. This comes as the company faces strategic challenges, including the patent expiration of its key insecticide Rynaxypyr and competitive pressures. FMC is concurrently implementing a 2026 operating plan focused on debt reduction and improving competitiveness.

While the strategic review is in preliminary stages with no guaranteed outcome, the market reacted positively to the possibility of a transaction. This positive movement occurred despite a separate analyst note from Citi which lowered the firm's price target on FMC shares.